Sign In
Buy COYA
$4.19
+0.110 (+2.70%)
At Close: Jul 31, 2026
Coya Therapeutics, Inc. (COYA) Upgraded to Buy: What Does It Mean for the Stock?
01:01pm, Wednesday, 25'th Feb 2026
Coya Therapeutics, Inc. (COYA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Coya Therapeutics Details ALS Combo Immunotherapy Plan, Highlights Early Biomarker Signals in Webinar
04:07am, Thursday, 19'th Feb 2026
Speakers on a Coya Therapeutics (NASDAQ: COYA) webinar outlined the company's scientific rationale and clinical development plans for an investigational combination immunotherapy in amyotrophic latera
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) functi
Coya Therapeutics Announces $11.1 Million Private Placement
08:00am, Friday, 30'th Jan 2026
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cel
Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders
08:00am, Tuesday, 20'th Jan 2026
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, relea
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cel
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cel
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cel
Coya Therapeutics Announces Patients Have Been Dosed in the ALSTARS Trial of COYA 302 for the Treatment of ALS
08:00am, Tuesday, 09'th Dec 2025
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cel
Coya Therapeutics to Participate in Upcoming Investor Relations and Clinical Trials Conferences
08:00am, Tuesday, 25'th Nov 2025
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cel
Coya Therapeutics, Inc. (NASDAQ:COYA) Given Consensus Rating of “Moderate Buy” by Brokerages
03:10am, Wednesday, 19'th Nov 2025
Coya Therapeutics, Inc. (NASDAQ: COYA - Get Free Report) has been assigned an average rating of "Moderate Buy" from the six analysts that are presently covering the stock, MarketBeat reports. One inve
Coya Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update
08:00am, Wednesday, 12'th Nov 2025
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) fun
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (T
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cel
Coya Therapeutics Announces Pricing of $20 Million Upsized Public Offering of Common Stock
06:30am, Friday, 24'th Oct 2025
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cel
